Preclinical efficacy of STRO-002 against FOLR1-expressing AML xenograft models. (A) Leukemia burden measured by bioluminescence (in vivo imaging system) imaging in MV4;11 FOLR1⁺ xenograft mice untreated or treated with STRO-002 at 2.5 mg/kg or 5 mg/kg weekly for 3 weeks. Shown are representative time points. N = 5 mice per group. (B) Quantification of radiance is shown in panel A. (C) Kaplan-Meier survival curves of MV4;11 FOLR1⁺ xenografts untreated or treated with STRO-002. Statistical differences in survival were evaluated using log-rank Mantel-Cox. (D,G) Leukemia burden measured by bioluminescence (in vivo imaging system) imaging in CBF/GLIS-transduced CB HSPC–bearing mice or WSU-AML–bearing mice untreated or treated with STRO-002 at 10 mg/kg weekly for 3 weeks, respectively. Shown are representative time points. N = 5 mice per group. (E,H) Quantification of radiance is shown in panels D and G, respectively. (F,I) Kaplan-Meier survival curves of CBF/GLIS-transduced CB HSPC–bearing mice or WSU-AML–bearing mice, respectively, untreated or treated with STRO-002. Statistical differences in survival were evaluated using log-rank Mantel-Cox. Symbol X indicates death. ND, not detected.